Preprints with The Lancet is part of SSRN´s First Look, a place where journals identify content of interest prior to publication. Authors have opted in at submission to The Lancet family of journals to post their preprints on Preprints with The Lancet. The usual SSRN checks and a Lancet-specific check for appropriateness and transparency have been applied. Preprints available here are not Lancet publications or necessarily under review with a Lancet journal. These preprints are early stage research papers that have not been peer-reviewed. The findings should not be used for clinical or public health decision making and should not be presented to a lay audience without highlighting that they are preliminary and have not been peer-reviewed. For more information on this collaboration, see the comments published in The Lancet about the trial period, and our decision to make this a permanent offering, or visit The Lancet´s FAQ page, and for any feedback please contact preprints@lancet.com.
Safety and Cross-Variant Immunogenicity of a Three-Dose COVID-19 mRNA Vaccine Regimen in Kidney Transplant Recipients
27 Pages Posted: 22 Jul 2021
More...Abstract
Background: The immunogenicity of a two-dose mRNA COVID-19 vaccine regimen is low in kidney transplant (KT) recipients. We report the first complete assessment of safety and cross-variant immunogenicity of a three-dose vaccine regimen in KT recipients.
Methods: We performed a prospective longitudinal study in sixty-one KT recipients given three doses of the BNT162b2 COVID-19 vaccine. We performed semi-structured pharmacovigilance interviews and monitored donor-specific antibodies and kidney function. We compared geometric mean titers (GMT) of anti-spike IgG, pseudo-neutralization activity against vaccine homologous and heterologous variants, frequency of spike-specific interferon (IFN)-γ-secreting cells, and antigen-induced cytokine production 28 days after the second and third doses. The immunoassays were also performed in non-transplanted individuals 28 days after the second dose to obtain reference values.
Findings: Reactions to vaccine were mild. One patient developed donor-specific anti-HLA antibodies after the second dose which could be explained by non-adherence to immunosuppressive therapy. Spike-specific IgG seroconversion raised from 44·3% (n=27) after the second dose to 62·3% (n=38) after the third dose (p<0·05). GMT increased from 528·3 (95% CI 300·0-930·1) to 2395 AU/ml (95% CI 1214-4724, p<0·0001). Serum neutralizing activity increased from 4·7% to 17·2% (Wuhan strain), 4·0% to 17·4% (alpha variant), 2·3% to 7·3% (beta variant), and 1·3% to 9·1% (gamma variant) after the third dose (p<0·0001), which remained lower than reference values. The mean frequency of IFN-γ-secreting cells increased from 19·9 (SD 56·0) to 64·0 (SD 76·8) cells/million PBMCs after the third dose (p<0·0001). A significant increase in IFN-γ responses was also observed in patients who remained seronegative after three doses (p<0·0001).
Interpretation: A third dose of the BNT162b2 vaccine increases both SARS-CoV-2-specific humoral and cellular responses in KT recipients with an acceptable tolerability profile. However, neutralizing antibody titres remain low after three doses, especially against variants of concern, and barrier measures and vaccination of the relatives remain essential.
Funding Information: This work was supported by grants from the Nice University Hospital (AOI) and the University of Cote d’Azur (IDEX).
Declaration of Interests: The authors declare no competing interests.
Ethics Approval Statement: The study protocol complies with the principles of the Declaration of Helsinki and was approved by our institutional committee. Written informed consent was obtained from all participants and all collected data and samples were anonymized and securely stored.
Suggested Citation: Suggested Citation